Advances in the development of bioprocesses for vaccines and viral vectors for gene therapy

In by

Spotlight Article


Overcoming Downstream Bottlenecks in Cell & Gene Therapy Manufacturing

Manuel Carrondo


Manuel Carrondo has been a Professor of Chemical and Biochemical Engineering at the University Nova de Lisboa for over 20 years. His key areas of research, from which over 230 papers have been published, include animal cell technology and its application for human and animal health; therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses as deliverables for gene therapy. Carrondo’s expertise has been tapped by advisory board roles at a number of companies and institutes, most recently the Fraunhofer Institute for Biomedical Engineering, iNOVA4Health Portugal and the OECD working party on Biotechnology, Nanotechnology and Converging Technologies. Earlier in his career he founded the Portuguese Academy of Engineering as well as iBET – Institute for Experimental and Technological Biology of which he is currently vice president. He has served as visiting professor at Carnegie- Mellon University and MIT, among others. Manuel Carrondo graduated in Chemical Engineering from Universidade do Porto in Portugal, followed by an MSc and PhD at Imperial College London in Environmental Engineering, and finally a Habilitation in Biochemical Engineering at his present university.

DOI: 10.18609/cgti.2017.053
Citation: Cell Gene Therapy Insights 2017; 3(6), 483-487.
Open access

This content is restricted to registered users. Click here to Register or Login here.